Product
Chenodeoxycholic acid
Aliases
CDCA, Chenodeoxycholic acid leadiant, Chenodeoxycholic acid Placebo
2 clinical trials
1 indication
Indication
Cerebrotendinous XanthomatosesClinical trial
Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) [Dose: 1 x 02 Capsules] Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid) [Dose: 1 x 02 Capsules] in Healthy Subjects Under Fasting ConditionsStatus: Completed, Estimated PCD: 2022-07-18
Clinical trial
A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Chenodeoxycholic Acid (CDCA), With an Open-Label Cohort, in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)Status: Not yet recruiting, Estimated PCD: 2025-11-30